Al Hammadi, Sudair Pharma ink MoU for potential acquisition

Al Hammadi Company for Development and Investment on Apr. 21 signed a two-month memorandum of understanding (MOU) with Sudair Pharma Co. for a potential acquisition.

Neither Al Hammadi nor its board of directors have any direct interest in the deal, the company said in a bourse statement on Sunday.

The transaction value is subject to the due diligence process, along with any other studies which Al Hammadi considers relevant to the transaction, as well as the required regulatory approvals.

The MoU may be extended upon mutual agreement by both parties.

The acquisition comes as part of Al Hammadi's growth plans and the Saudi Vision 2030 to nationalize advanced industries and technologies. It will also help Al Hammadi capitalize on the significant growth expected in the manufacturing and distribution of specialized drugs.

The cancer drugs manufacturing plant is the first stage of Sudair Pharma complex, the largest pharmaceutical project specialized in the manufacturing of cancer treatments in the Kingdom.

The 77,000-square meter project comprises research centers, a training academy and administrative buildings.

Al Hammadi will announce any further developments in due course, the statement added.